Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Dec 30;14(4):737-744.
doi: 10.34172/apb.43306. Epub 2024 Sep 15.

Targeted Therapy Evolution from Defining a Sub-population to Crossing Multi-indications

Daohong Chen  1
Affiliations
Editorial

Targeted Therapy Evolution from Defining a Sub-population to Crossing Multi-indications

Daohong Chen. Adv Pharm Bull. .

Abstract

Purpose: It tends not only to shed lights on an emerging classification framework of disease according to the shared molecular pathogenesis across various organs/tissues, but also to inspire more efficient paradigms of pharmaceutic innovation in a broader medical perspective.

Methods: Literature review and re-thinking.

Results: This article has sorted out an updated profile of the outstanding targeted medications with an extending list of clinical indications in oncology and beyond.

Conclusion: Pharmaceutic development can be processed in a less risky and more affordable manner through drug repurpose or tissue agnostic approval.

Keywords: Drug repurpose; Targeted therapy; Tissue agnostic approval.

PubMed Disclaimer

Conflict of interest statement

None declared.

References

    1. Rulten SL, Grose RP, Gatz SA, Jones JL, Cameron AJM. The future of precision oncology. Int J Mol Sci. 2023;24(16):12613. doi: 10.3390/ijms241612613. - DOI - PMC - PubMed
    1. Stuart DD, Guzman-Perez A, Brooijmans N, Jackson EL, Kryukov GV, Friedman AA, et al. Precision oncology comes of age: designing best-in-class small molecules by integrating two decades of advances in chemistry, target biology, and data science. Cancer Discov. 2023;13(10):2131–49. doi: 10.1158/2159-8290.cd-23-0280. - DOI - PMC - PubMed
    1. Min HY, Lee HY. Molecular targeted therapy for anticancer treatment. Exp Mol Med. 2022;54(10):1670–94. doi: 10.1038/s12276-022-00864-3. - DOI - PMC - PubMed
    1. Chen DH, Zhang XS. Targeted therapy: resistance and re-sensitization. Chin J Cancer. 2015;34(11):496–501. doi: 10.1186/s40880-015-0047-1. - DOI - PMC - PubMed
    1. Serelli-Lee V, Ito K, Koibuchi A, Tanigawa T, Ueno T, Matsushima N, et al. A state-of-the-art roadmap for biomarker-driven drug development in the era of personalized therapies. J Pers Med. 2022;12(5):669. doi: 10.3390/jpm12050669. - DOI - PMC - PubMed

Publication types

LinkOut - more resources